Sight Sciences' newest MIGS device gains FDA clearance for single-pass canaloplasty and trabeculotomy in open-angle glaucoma.

How does minimally invasive glaucoma surgery help patients manage glaucoma earlier and with fewer medications?

Sight Sciences’ OMNI Ultra receives US FDA 510(k) clearance for canaloplasty; plans US commercial launch in fourth quarter of 2026: Menlo Park, California Thursday, August 6, 20 ...

Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company, today announced U.S. Food and Drug Administration (FDA) ...

Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to ...

Built in 1954 and capable of speeds exceeding 540 mph (870 km/h), the Soviet MiG-15 became one of the most influential fighter jets in aviation history. Famous for its role during the Korean War, this ...

New system expands the Company’s leadership in interventional glaucoma with the first FDA cleared MIGS device for single pass canaloplasty with TruSync™ Plus innovation.

Your team spent three months writing production-grade inference code. The model is tuned. The pipeline is tested. The ...

A look at a MiG-23 inside a hangar, with commentary and reactions around the aircraft and what makes the scene stand out. A ...

An announcement from Glaukos ( (GKOS) ) is now available.

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal ...

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today ...